Skip to main content Skip to search Skip to main navigation

MDR: Proposal for a delay due to Covid-19

The deadline of 26 May 2020 should have been the date: The European Commission's Medical Device Regulation (MDR) was supposed to come into force. Due to the Corona crisis, the European Commission is now submitting a proposal to postpone the implementation deadline.

Other organisations had already called for this step:

Medical device manufacturers have repeatedly questioned whether the deadline can be met, as there is still a lack of Notified Bodies. The introduction of laws to ensure compliance with the new product standards was also critical in terms of timing (we reported).

In a press release of 23 March 2020, MedTech Europe called for a postponement of the introduction date for MDR and IVDR. Their proposal: Six months after the crisis has been overcome, the implementation should be resumed.

In a letter of 24 March 2020, six Members of the European Parliament address the lack of resources caused by the current crisis in the following areas:

  • Approval of clinical trials
  • Notification and auditing of Notified Bodies
  • Manufacturing

The Members of Parliament are calling to maintain the current system for regulating medical devices. Health systems across Europe need all their resources to deal with the corona crisis.

The proposal for postponement should be submitted in early April and implemented as soon as possible. This information is according to a Q&A session at the European Commission press conference of 25 March 2020.


Sources:

MedTech Europe: Press release

European Commission: Letter of the European Parliament

European Commission: Q&A Press conference Covid-19 and MDR

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: Updated Q&A on OOS Batches of ATMPs

EMA: Updated Q&A on OOS Batches of ATMPs

The EMA has revised its questions and answers on the use of out-of-specification (OOS) batches of authorised cell- and tissue-based ATMPs (“Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based ATMPs”, Rev. 1, 2026).
Read more
Previous
Next